Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARγ up-expression in MDA-MB-231 cells

Exp Mol Pathol. 2011 Dec;91(3):768-74. doi: 10.1016/j.yexmp.2011.09.007. Epub 2011 Sep 10.

Abstract

No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Ligand activation of peroxisome-activated receptor (PPAR)γ induces antitumor effects in cancer but not obviously in TNBC. In TNBC cells, combined treatment with thiazolidinedione and demethylation drugs Hydralazine up-regulated protein and mRNA levels of PPARγ. Besides, the combination of two drugs promote antiproliferative and apoptotic effects in TNBC cells and decrease the proliferation index in the tumor xenografts. Taken together, our results suggest that multidrug regimens including a combination of Thiazolidinedione and Hydralazine may provide a therapeutic advantage in TNBC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Drug Therapy, Combination
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Hydralazine* / pharmacology
  • Hydralazine* / therapeutic use
  • Ligands
  • Molecular Targeted Therapy
  • PPAR gamma / agonists
  • PPAR gamma / biosynthesis*
  • PPAR gamma / genetics
  • Receptor, ErbB-2 / biosynthesis
  • Thiazolidinediones* / pharmacology
  • Thiazolidinediones* / therapeutic use
  • Up-Regulation / drug effects

Substances

  • Ligands
  • PPAR gamma
  • Thiazolidinediones
  • Hydralazine
  • ERBB2 protein, human
  • Receptor, ErbB-2